Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 18;79(12):1273-7.
doi: 10.1212/WNL.0b013e31826aac4e. Epub 2012 Aug 22.

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

Joanna Kitley  1 , Mark Woodhall, Patrick Waters, M Isabel Leite, Emma Devenney, John Craig, Jacqueline Palace, Angela Vincent
Affiliations

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

Joanna Kitley et al. Neurology. .

Abstract

Objectives: To report an association of myelin-oligodendrocyte glycoprotein (MOG) antibodies with aquaporin-4 (AQP4) antibody-seronegative neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) in adults.

Methods: We describe the clinical and serologic features of 4 adult patients with an NMO/NMOSD phenotype who had antibodies to MOG.

Results: Twenty-seven adult AQP4-seronegative NMO/NMOSD patients were tested for MOG antibodies. Four patients (3 male, 1 female) with severe optic neuritis and/or longitudinally extensive transverse myelitis were positive. All 4 made good recoveries with steroids or plasma exchange. Two patients experienced recurrence of symptoms when corticosteroids were withdrawn quickly but none have experienced further relapses over a mean follow-up of 12 months, although 3 patients remain on treatment. Imaging abnormalities resolved fully following clinical recovery and MOG antibody titers fell in all 4 patients. MOG antibodies were not found in 44 AQP4 antibody-positive NMO/NMOSD patients, 75 adult patients with multiple sclerosis, or 47 healthy individuals.

Conclusions: MOG antibody-associated NMO/NMOSD could account for some cases thought previously to be AQP4-seronegative NMO/NMOSD. Our 4 patients appear to have more favorable clinical outcomes than those with typical AQP4 antibody-mediated disease. However, further studies of NMO/NMOSD and other demyelinating conditions are required to help clarify the diagnostic and prognostic relevance of MOG antibodies.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • Origins and significance of astrogliosis in the multiple sclerosis model, MOG peptide EAE.
    Moreno M, Guo F, Mills Ko E, Bannerman P, Soulika A, Pleasure D. Moreno M, et al. J Neurol Sci. 2013 Oct 15;333(1-2):55-9. doi: 10.1016/j.jns.2012.12.014. Epub 2013 Jan 5. J Neurol Sci. 2013. PMID: 23294494 Free PMC article. Review.
  • Treatment of MOG antibody associated disorders: results of an international survey.
    Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A. Whittam DH, et al. J Neurol. 2020 Dec;267(12):3565-3577. doi: 10.1007/s00415-020-10026-y. Epub 2020 Jul 4. J Neurol. 2020. PMID: 32623595 Free PMC article.
  • Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T. Fernandez-Carbonell C, et al. Mult Scler. 2016 Feb;22(2):174-84. doi: 10.1177/1352458515587751. Epub 2015 Jun 3. Mult Scler. 2016. PMID: 26041801 Free PMC article.
  • MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). Jarius S, et al. J Neuroinflammation. 2016 Sep 26;13(1):279. doi: 10.1186/s12974-016-0717-1. J Neuroinflammation. 2016. PMID: 27788675 Free PMC article.
  • Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children.
    Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, Palace J, Wassmer E, Tardieu M, Vincent A, Lim M, Waters P. Hacohen Y, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(2):e81. doi: 10.1212/NXI.0000000000000081. eCollection 2015 Apr. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 25798445 Free PMC article.
See all "Cited by" articles

LinkOut - more resources